Ensysce Biosciences (ENSCW) EBT Margin (2020 - 2025)
Historic EBT Margin for Ensysce Biosciences (ENSCW) over the last 6 years, with Q3 2025 value amounting to 759.97%.
- Ensysce Biosciences' EBT Margin fell 7787100.0% to 759.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 246.43%, marking a year-over-year decrease of 669900.0%. This contributed to the annual value of 153.94% for FY2024, which is 3424500.0% up from last year.
- As of Q3 2025, Ensysce Biosciences' EBT Margin stood at 759.97%, which was down 7787100.0% from 127.87% recorded in Q2 2025.
- Ensysce Biosciences' EBT Margin's 5-year high stood at 18.74% during Q3 2024, with a 5-year trough of 3418.77% in Q2 2022.
- In the last 5 years, Ensysce Biosciences' EBT Margin had a median value of 467.7% in 2023 and averaged 764.75%.
- Per our database at Business Quant, Ensysce Biosciences' EBT Margin plummeted by -31211600bps in 2022 and then surged by 29510700bps in 2023.
- Quarter analysis of 5 years shows Ensysce Biosciences' EBT Margin stood at 123.48% in 2021, then plummeted by -253bps to 436.19% in 2022, then crashed by -56bps to 679.66% in 2023, then skyrocketed by 60bps to 275.17% in 2024, then crashed by -176bps to 759.97% in 2025.
- Its last three reported values are 759.97% in Q3 2025, 127.87% for Q2 2025, and 149.37% during Q1 2025.